EBV viral load detection in clinical virology

Journal of Clinical Virology

Volumn 48, Issue 2, 2010, Pages 82-90

  Gärtner, Barbara ^a   Preiksaitis, Jutta K ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

EBV viral load; HIV lymphoma; Nasopharyngeal carcinoma; Post transplant lymphoproliferating diseases; Transplant recipients

Indexed keywords

BAMHI A RIGHTWARD TRANSCRIPT RNA; GENE PRODUCT; GENOMIC DNA; UNCLASSIFIED DRUG; VIRUS DNA;

AIDS PATIENT; CEREBROSPINAL FLUID ANALYSIS; EPSTEIN BARR VIRUS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; MEASUREMENT; NASOPHARYNX CARCINOMA; ORGAN TRANSPLANTATION; OROPHARYNX; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PLASMA; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECIPIENT; REVIEW; SEROLOGY; SERUM; VIROGENESIS; VIRUS ENCEPHALITIS; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION; VIRUS LOAD;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; VIRAL LOAD;

EID: 77951652459     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.03.016     Document Type: Review

References (105)

1. Pohl D. Epstein-Barr virus and multiple sclerosis. J Neurol Sci (2009)
2. Toussirot E., and Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 22 (2008) 883-896
3. Gulley M.L., and Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 10 (2008) 279-292
4. Swerdlow S.H., Webber S.A., Chadburn A., and Ferry J.A. Post-transplant lymphoproliferative disorders. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., and Stein H. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. (2008), WHO Press, Geneva 343-344
5. Preiksaitis J.K. Epstein-Barr viral load testing: role in the prevention, diagnosis and management of posttransplant lymphoproliferative disorders. In: Dharnidharka V.R., Green M., and Webber S.A. (Eds). Post-transplant lymphoproliferative disorders (2009), Springer Verlag, Berlin Heidelberg 45-69
6. De Paoli P., Pratesi C., and Bortolin M.T. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 133 (2007) 809-815
7. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?. Rev Med Virol 16 (2006) 251-261
8. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., Harijadi, Paramita D.K., Fachiroh J., et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119 (2006) 608-614
9. Maurmann S., Fricke L., Wagner H.J., Schlenke P., Hennig H., Steinhoff J., et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 41 (2003) 5419-5428
10. Fafi-Kremer S., Morand P., Brion J.P., Pavese P., Baccard M., Germi R., et al. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis 191 (2005) 985-989
11. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., Harijadi, Fachiroh J., Paramita D.K., et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43 (2005) 3066-3073
12. Chan K.C., Zhang J., Chan A.T., Lei K.I., Leung S.F., Chan L.Y., et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63 (2003) 2028-2032
13. Hakim H., Gibson C., Pan J., Srivastava K., Gu Z., Bankowski M.J., et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol 45 (2007) 2151-2155
14. Hayden R.T., Hokanson K.M., Pounds S.B., Bankowski M.J., Belzer S.W., Carr J., et al. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol 46 (2008) 157-163
15. Fafi-Kremer S., Morand P., Germi R., Ballout M., Brion J.P., Genoulaz O., et al. A prospective follow-up of Epstein-Barr virus LMP1 genotypes in saliva and blood during infectious mononucleosis. J Infect Dis 192 (2005) 2108-2111
16. Sitki-Green D.L., Edwards R.H., Covington M.M., and Raab-Traub N. Biology of Epstein-Barr virus during infectious mononucleosis. J Infect Dis 189 (2004) 483-492
17. Babcock G.J., Decker L.L., Freeman R.B., and Thorley-Lawson D.A. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190 (1999) 567-576
18. Souza T.A., Stollar B.D., Sullivan J.L., Luzuriaga K., and Thorley-Lawson D.A. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci USA 102 (2005) 18093-18098
19. Rose C., Green M., Webber S., Kingsley L., Day R., Watkins S., et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol 40 (2002) 2533-2544
20. Schauer E., Webber S., Kingsley L., Green M., and Rowe D. Increased Ig-null B lymphocytes in the peripheral blood of pediatric solid organ transplant recipients with elevated Epstein-Barr viral loads. Pediatr Transplant 13 (2009) 311-318
21. Hopwood P.A., Brooks L., Parratt R., Hunt B.J., Bokhari M., Thomas J.A., et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 74 (2002) 194-202
22. Bekker V., Scherpbier H., Beld M., Piriou E., van Breda A., Lange J., et al. Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. J Infect Dis 194 (2006) 1323-1330
23. Ryan J.L., Fan H., Swinnen L.J., Schichman S.A., Raab-Traub N., Covington M., et al. Epstein-Barr virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 13 (2004) 61-68
24. Kimura H., Ito Y., Suzuki R., and Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 18 (2008) 305-319
25. Hadinoto V., Shapiro M., Sun C.C., and Thorley-Lawson D.A. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 5 (2009) e1000496
26. Hadinoto V., Shapiro M., Greenough T.C., Sullivan J.L., Luzuriaga K., and Thorley-Lawson D.A. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 111 (2008) 1420-1427
27. Kullberg-Lindh C., Olofsson S., Brune M., and Lindh M. Comparison of serum and whole blood levels of cytomegalovirus and Epstein-Barr virus DNA. Transpl Infect Dis 10 (2008) 308-315
28. Fafi-Kremer S., Brengel-Pesce K., Bargues G., Bourgeat M.J., Genoulaz O., Seigneurin J.M., et al. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol 30 (2004) 157-164
29. Stevens S.J., Pronk I., and Middeldorp J.M. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 39 (2001) 1211-1216
30. Bauer C.C., Aberle S.W., Popow-Kraupp T., Kapitan M., Hofmann H., and Puchhammer-Stockl E. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol 75 (2005) 54-58
31. Luderer R., Kok M., Niesters H.G., Schuurman R., de Weerdt O., and Thijsen S.F. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. Mol Diagn 9 (2005) 195-200
32. Laroche C., Drouet E.B., Brousset P., Pain C., Boibieux A., Biron F., et al. Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas. J Med Virol 46 (1995) 66-74
33. Kimura H., Hoshino Y., Kanegane H., Tsuge I., Okamura T., Kawa K., et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98 (2001) 280-286
34. Kimura H., Nishikawa K., Hoshino Y., Sofue A., Nishiyama Y., and Morishima T. Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection. Med Microbiol Immunol (Berl) 188 (2000) 197-202
35. Fan H., Nicholls J., Chua D., Chan K.H., Sham J., Lee S., et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 112 (2004) 1036-1041
36. Lin J.C., Wang W.Y., Liang W.M., Chou H.Y., Jan J.S., Jiang R.S., et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1342-1348
37. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350 (2004) 2461-2470
38. Houali K., Wang X., Shimizu Y., Djennaoui D., Nicholls J., Fiorini S., et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 13 (2007) 4993-5000
39. To E.W., Chan K.C., Leung S.F., Chan L.Y., To K.F., Chan A.T., et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9 (2003) 3254-3259
40. Lei K.I., Chan L.Y., Chan W.Y., Johnson P.J., and Lo Y.M. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 8 (2002) 29-34
41. Lei K.I., Chan L.Y., Chan W.Y., Johnson P.J., and Lo Y.M. Circulating cell-free Epstein-Barr virus DNA levels in patients with EBV-associated lymphoid malignancies. Ann N Y Acad Sci 945 (2001) 80-83
42. Gandhi M.K., Lambley E., Burrows J., Dua U., Elliott S., Shaw P.J., et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 12 (2006) 460-464
43. Jo S.A., Hwang S.H., Kim S.Y., Shin H.J., Chung J.S., Sol M.Y., et al. Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin's lymphoma. Int J Lab Hematol (2009)
44. Weinstock D.M., Ambrossi G.G., Brennan C., Kiehn T.E., and Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 37 (2006) 539-546
45. Clave E., Agbalika F., Bajzik V., de Latour R.P., Trillard M., Rabian C., et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 77 (2004) 76-84
46. Meij P., van Esser J.W., Niesters H.G., van Baarle D., Miedema F., Blake N., et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101 (2003) 4290-4297
47. Sebelin-Wulf K., Nguyen T.D., Oertel S., Papp-Vary M., Trappe R.U., Schulzki A., et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 17 (2007) 203-210
48. Smets F., Latinne D., Bazin H., Reding R., Otte J.B., Buts J.P., et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73 (2002) 1603-1610
49. Funk G.A., Gosert R., and Hirsch H.H. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 7 (2007) 460-472
50. Styczynski J., Einsele H., de la Camara R., Cordonnier C., Engelhard D., Reusser P., Ward K.N., and Ljungman P. Guidelines for EBV management in patients with leukemia and other hematological disorders. 2009 update of ECIL. 3rd European Conference on Infections in Leukemia (2009). http://www.ichs.org/Ecilslides/ECIL3%2520EBV%2520Guidelines%2520Update%2 5202009.pdf http://www.ichs.org/Ecilslides/ECIL3%20EBV%20Guidelines%20Update%202009. pdf
51. Kasiske B.L., Zeier M.G., Chapman J.R., Craig J.C., Ekberg H., Garvey C.A., et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77 (2010) 299-311
52. Tsai D.E., Douglas L., Andreadis C., Vogl D.T., Arnoldi S., Kotloff R., et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 8 (2008) 1016-1024
53. Green M., Cacciarelli T.V., Mazariegos G.V., Sigurdsson L., Qu L., Rowe D.T., et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 66 (1998) 1641-1644
54. Oertel S., Trappe R.U., Zeidler K., Babel N., Reinke P., Hummel M., et al. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 85 (2006) 478-484
55. Yang J., Tao Q., Flinn I.W., Murray P.G., Post L.E., Ma H., et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96 (2000) 4055-4063
56. D'Antiga L., Del Rizzo M., Mengoli C., Cillo U., Guariso G., and Zancan L. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 13 (2007) 343-348
57. Green M., Soltys K., Rowe D.T., Webber S.A., and Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 13 (2009) 319-323
58. van Esser J.W., Niesters H.G., Thijsen S.F., Meijer E., Osterhaus A.D., Wolthers K.C., et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 113 (2001) 814-821
59. Bingler M.A., Feingold B., Miller S.A., Quivers E., Michaels M.G., Green M., et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8 (2008) 442-445
60. Doesch A.O., Konstandin M., Celik S., Kristen A., Frankenstein L., Sack F.U., et al. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transpl Int 21 (2008) 963-971
61. Schubert S., Renner C., Hammer M., Abdul-Khaliq H., Lehmkuhl H.B., Berger F., et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 27 (2008) 100-105
62. Ahya V.N., Douglas L.P., Andreadis C., Arnoldi S., Svoboda J., Kotloff R.M., et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 26 (2007) 839-844
63. Humar A., and Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6 (2006) 262-274
64. Lee T.C., Savoldo B., Rooney C.M., Heslop H.E., Gee A.P., Caldwell Y., et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 5 (2005) 2222-2228
65. Bakker N.A., Verschuuren E.A., Erasmus M.E., Hepkema B.G., Veeger N.J., Kallenberg C.G., et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 83 (2007) 433-438
66. Stevens S.J., Smits P.H., Verkuijlen S.A., Rockx D.A., van Gorp E.C., Mulder J.W., et al. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 21 (2007) 2141-2149
67. Ling P.D., Vilchez R.A., Keitel W.A., Poston D.G., Peng R.S., White Z.S., et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 37 (2003) 1244-1249
68. Webster-Cyriaque J., Middeldorp J., and Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 74 (2000) 7610-7618
69. Fan H., Kim S.C., Chima C.O., Israel B.F., Lawless K.M., Eagan P.A., et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 75 (2005) 59-69
70. Bonnet F., Jouvencel A.C., Parrens M., Leon M.J., Cotto E., Garrigue I., et al. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 36 (2006) 258-263
71. Van Baarle D., Wolthers K.C., Hovenkamp E., Niesters H.G., Osterhaus A.D., Miedema F., et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 186 (2002) 405-409
72. Doja A., Bitnun A., Ford Jones E.L., Richardson S., Tellier R., Petric M., et al. Pediatric Epstein-Barr virus-associated encephalitis: 10-year review. J Child Neurol 21 (2006) 384-391
73. Bossolasco S., Cinque P., Ponzoni M., Vigano M.G., Lazzarin A., Linde A., et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 8 (2002) 432-438
74. Cinque P., Vago L., Dahl H., Brytting M., Terreni M.R., Fornara C., et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10 (1996) 951-958
75. Corcoran C., Rebe K., van der Plas H., Myer L., and Hardie D.R. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 42 (2008) 433-436
76. Weinberg A., Li S., Palmer M., and Tyler K.L. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Ann Neurol 52 (2002) 543-548
77. Rose C., Green M., Webber S., Ellis D., Reyes J., and Rowe D. Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin d-negative B-cell compartment. J Clin Microbiol 39 (2001) 1407-1415
78. Schauer E., Webber S., Green M., and Rowe D. Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients. J Clin Microbiol 42 (2004) 5802-5810
79. Laichalk L.L., and Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79 (2005) 1296-1307
80. Lucas K.G., Burton R.L., Zimmerman S.E., Wang J., Cornetta K.G., Robertson K.A., et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91 (1998) 3654-3661
81. Ohga S., Kanaya Y., Maki H., Takada H., Ohshima K., Kanda M., et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transplant 25 (2000) 209-212
82. Hoshino Y., Kimura H., Kuzushima K., Tsurumi T., Nemoto K., Kikuta A., et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant 26 (2000) 199-201
83. van Esser J.W., van der Holt B., Meijer E., Niesters H.G., Trenschel R., Thijsen S.F., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98 (2001) 972-978
84. Gartner B.C., Schafer H., Marggraff K., Eisele G., Schafer M., Dilloo D., et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 40 (2002) 351-358
85. Lankester A.C., van Tol M.J., Vossen J.M., Kroes A.C., and Claas E. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 99 (2002) 2630-2631
86. Sirvent-Von Bueltzingsloewen A., Morand P., Buisson M., Souillet G., Chambost H., Bosson J.L., et al. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant 29 (2002) 21-28
87. Wagner H.J., Cheng Y.C., Huls M.H., Gee A.P., Kuehnle I., Krance R.A., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103 (2004) 3979-3981
88. Greenfield H.M., Gharib M.I., Turner A.J., Guiver M., Carr T., Will A.M., et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?. Pediatr Blood Cancer 47 (2006) 200-205
89. Kinch A., Oberg G., Arvidson J., Falk K.I., Linde A., and Pauksens K. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 39 (2007) 235-244
90. Aalto S.M., Juvonen E., Tarkkanen J., Volin L., Haario H., Ruutu T., et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 45 (2007) 1305-1309
91. Meerbach A., Wutzler P., Hafer R., Zintl F., and Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 80 (2008) 441-454
92. Rowe D.T., Qu L., Reyes J., Jabbour N., Yunis E., Putnam P., et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35 (1997) 1612-1615
93. Lucas K.G., Filo F., Heilman D.K., Lee C.H., and Emanuel D.J. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood 92 (1998) 3977-3978
94. McDiarmid S.V., Jordan S., Kim G.S., Toyoda M., Goss J.A., Vargas J.H., et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66 (1998) 1604-1611
95. Green M., Bueno J., Rowe D., Mazariegos G., Qu L., Abu-Almagd K., et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70 (2000) 593-596
96. Gridelli B., Spada M., Riva S., Colledan M., Segalin A., Lucianetti A., et al. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation. Transpl Int 13 Suppl. 1 (2000) S399-S401
97. Vajro P., Lucariello S., Migliaro F., Sokal E., Gridelli B., Vegnente A., et al. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis 181 (2000) 2050-2054
98. Baldanti F., Grossi P., Furione M., Simoncini L., Sarasini A., Comoli P., et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 38 (2000) 613-619
99. Allen U., Hebert D., Petric M., Tellier R., Tran D., Superina R., et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 33 (2001) 145-150
100. Matsukura T., Yokoi A., Egawa H., Kudo T., Kawashima M., Hirata Y., et al. Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clin Transplant 16 (2002) 107-112
101. Orentas R.J., Schauer Jr. D.W., Ellis F.W., Walczak J., Casper J.T., and Margolis D.A. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 7 (2003) 305-314
102. Yancoski J., Danielian S., Ibanez J., Turconi A., Cuarterolo M., Zelazko M., et al. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR. J Clin Virol 31 (2004) 58-65
103. Lo Y.M., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59 (1999) 5452-5455
104. Lo Y.M., Chan A.T., Chan L.Y., Leung S.F., Lam C.W., Huang D.P., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60 (2000) 6878-6881
105. Gotoh K., Ito Y., Shibata-Watanabe Y., Kawada J., Takahashi Y., Yagasaki H., et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 46 (2008) 1525-1534